Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with 177 Lu-PSMA

Sobhan Moazemi, Annette Erle, Susanne Lütje, Florian C. Gaertner, Markus Essler, and Ralph A. Bundschuh
In: Diagnostics (2021), 11:2(186)
 

Abstract

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate disease. Radiomics signature (RS) is widely used for the analysis of overall survival (OS) in cancer diseases. This study aims at investigating the role of radiomics features (RFs) and RS from pretherapeutic gallium-68 (68Ga)-PSMA-PET/CT findings and patient-specific clinical parameters to analyze overall survival of prostate cancer (PC) patients when treated with lutethium-177 (177Lu)-PSMA. A cohort of 83 patients with advanced PC was retrospectively analyzed. Average values of 73 RFs of 2070 malignant hotspots as well as 22 clinical parameters were analyzed for each patient. From the Cox proportional hazard model, the least absolute shrinkage and selection operator (LASSO) regularization method is used to select most relevant features (standardized uptake value (SUV)Min and kurtosis with the coefficients of 0.984 and −0.118, respectively) and to calculate the RS from the RFs. Kaplan–Meier (KM) estimator was used to analyze the potential of RFs and conventional clinical parameters, such as metabolic tumor volume (MTV) and standardized uptake value (SUV) for the prediction of survival. As a result, SUVMin, kurtosis, the calculated RS, SUVMean, as well as Hemoglobin (Hb)1, C-reactive protein (CRP)1, and ECOG1 (clinical parameters) achieved p-values less than 0.05, which suggest the potential of findings from 68Ga-PSMA-PET/CT scans as well as patient-specific clinical parameters for the prediction of OS for patients with advanced PC treated with 177Lu-PSMA therapy.

Images

Bibtex

@ARTICLE{Moazemi:Diagnostics2021,
    author = {Moazemi, Sobhan and Erle, Annette and L{\"u}tje, Susanne and Gaertner, Florian C. and Essler, Markus
              and Bundschuh, Ralph A.},
     pages = {186},
     title = {Estimating the Potential of Radiomics  Features and Radiomics Signature from Pretherapeutic
              PSMA-PET-CT Scans and  Clinical Data for Prediction of Overall Survival When Treated with ^{177}
              Lu-PSMA},
   journal = {Diagnostics},
    volume = {11},
    number = {2},
      year = {2021},
  abstract = {Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography
              (PSMA-PET/CT) scans can facilitate diagnosis and treatment of prostate disease. Radiomics signature
              (RS) is widely used for the analysis of overall survival (OS) in cancer diseases. This study aims at
              investigating the role of radiomics features (RFs) and RS from pretherapeutic gallium-68
              (68Ga)-PSMA-PET/CT findings and patient-specific clinical parameters to analyze overall survival of
              prostate cancer (PC) patients when treated with lutethium-177 (177Lu)-PSMA. A cohort of 83 patients
              with advanced PC was retrospectively analyzed. Average values of 73 RFs of 2070 malignant hotspots
              as well as 22 clinical parameters were analyzed for each patient. From the Cox proportional hazard
              model, the least absolute shrinkage and selection operator (LASSO) regularization method is used to
              select most relevant features (standardized uptake value (SUV)Min and kurtosis with the coefficients
              of 0.984 and −0.118, respectively) and to calculate the RS from the RFs. Kaplan–Meier (KM)
              estimator was used to analyze the potential of RFs and conventional clinical parameters, such as
              metabolic tumor volume (MTV) and standardized uptake value (SUV) for the prediction of survival. As
              a result, SUVMin, kurtosis, the calculated RS, SUVMean, as well as Hemoglobin (Hb)1, C-reactive
              protein (CRP)1, and ECOG1 (clinical parameters) achieved p-values less than 0.05, which suggest the
              potential of findings from 68Ga-PSMA-PET/CT scans as well as patient-specific clinical parameters
              for the prediction of OS for patients with advanced PC treated with 177Lu-PSMA therapy.}
}